John Frederick De Groot

2.0k total citations
51 papers, 312 citations indexed

About

John Frederick De Groot is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Frederick De Groot has authored 51 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 20 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Frederick De Groot's work include Glioma Diagnosis and Treatment (36 papers), Radiomics and Machine Learning in Medical Imaging (11 papers) and Cancer, Hypoxia, and Metabolism (9 papers). John Frederick De Groot is often cited by papers focused on Glioma Diagnosis and Treatment (36 papers), Radiomics and Machine Learning in Medical Imaging (11 papers) and Cancer, Hypoxia, and Metabolism (9 papers). John Frederick De Groot collaborates with scholars based in United States, Canada and Switzerland. John Frederick De Groot's co-authors include Howard Colman, Patrick Y. Wen, David A. Reardon, Sarah Gaffey, Timothy F. Cloughesy, Jennifer Clarke, Katherine B. Peters, Phioanh L. Nghiemphu, Justin T. Jordan and Barbara O’Brien and has published in prestigious journals such as Journal of Clinical Oncology.

In The Last Decade

John Frederick De Groot

46 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Frederick De Groot United States	10	219	157	95	71	62	51	312
Enrico C. Lallana United States	7	236 1.1×	137 0.9×	87 0.9×	120 1.7×	51 0.8×	8	356
Sarah Gaffey United States	9	243 1.1×	148 0.9×	79 0.8×	71 1.0×	152 2.5×	22	402
Theresa Bunse Germany	10	211 1.0×	145 0.9×	43 0.5×	153 2.2×	93 1.5×	17	343
Prajwal Rajappa United States	12	140 0.6×	77 0.5×	61 0.6×	61 0.9×	62 1.0×	31	263
Frank Bouttens Belgium	8	231 1.1×	104 0.7×	79 0.8×	33 0.5×	114 1.8×	15	327
Anuspandana Mahapatra India	7	163 0.7×	167 1.1×	51 0.5×	63 0.9×	195 3.1×	19	407
Shirley Ong United States	8	113 0.5×	92 0.6×	63 0.7×	32 0.5×	66 1.1×	18	215
Ryan Merrell United States	10	146 0.7×	89 0.6×	59 0.6×	28 0.4×	47 0.8×	35	261
Patrícia Domingues Portugal	3	172 0.8×	81 0.5×	104 1.1×	98 1.4×	165 2.7×	10	390
Hisashi Hatano Japan	8	183 0.8×	112 0.7×	108 1.1×	44 0.6×	135 2.2×	13	365

Countries citing papers authored by John Frederick De Groot

Since Specialization

Citations

This map shows the geographic impact of John Frederick De Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Frederick De Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Frederick De Groot more than expected).

Fields of papers citing papers by John Frederick De Groot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Frederick De Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Frederick De Groot. The network helps show where John Frederick De Groot may publish in the future.

Co-authorship network of co-authors of John Frederick De Groot

This figure shows the co-authorship network connecting the top 25 collaborators of John Frederick De Groot. A scholar is included among the top collaborators of John Frederick De Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Frederick De Groot. John Frederick De Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Groot, John Frederick De, Timothy F. Cloughesy, Donald A. Berry, et al.. (2024). Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2005–2005.

O’Brien, Barbara, Rashmi K. Murthy, Donald A. Berry, et al.. (2024). Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.. Journal of Clinical Oncology. 42(16_suppl). 2018–2018. 4 indexed citations

Krishna, Saritha, Cesar Nava Gonzales, Youssef Sibih, et al.. (2024). Can targeting TSP-1 with gabapentin enhance survival in glioblastoma? A 20-year retrospective cohort study.. Journal of Clinical Oncology. 42(16_suppl). 2048–2048. 3 indexed citations

Ahluwalia, Manmeet S., Ahmad Ozair, Arjun Sahgal, et al.. (2024). A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).. Journal of Clinical Oncology. 42(16_suppl). TPS2098–TPS2098. 3 indexed citations

Majd, Nazanin, D.N. Yeboa, Shuqi Wang, et al.. (2024). Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2076–2076. 3 indexed citations

Ahluwalia, Manmeet S., Michael McDermott, Terry C. Burns, et al.. (2023). Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).. Journal of Clinical Oncology. 41(16_suppl). TPS2084–TPS2084. 1 indexed citations

Goldlust, Samuel, Jong Hee Chang, Yoshitaka Narita, et al.. (2023). Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).. Journal of Clinical Oncology. 41(16_suppl). 2022–2022. 1 indexed citations

Wen, Patrick Y., Martin J. van den Bent, Gilbert Youssef, et al.. (2023). RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade gliomas in adults.. Journal of Clinical Oncology. 41(16_suppl). 2017–2017. 5 indexed citations

Cloughesy, Timothy F., Brian M. Alexander, Donald A. Berry, et al.. (2022). GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology. 40(16_suppl). TPS2078–TPS2078. 4 indexed citations

10.

Majd, Nazanin, Heather Lin, Ying Yuan, et al.. (2020). Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab.. Journal of Clinical Oncology. 38(15_suppl). 2559–2559. 2 indexed citations

11.

Weathers, Shiao‐Pei, Carlos Kamiya-Matsuoka, Rebecca A. Harrison, et al.. (2020). Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology. 38(15_suppl). 2511–2511. 14 indexed citations

12.

Arrillaga‐Romany, Isabel, Sylvia C. Kurz, Rohinton S. Tarapore, et al.. (2020). Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. Journal of Clinical Oncology. 38(15_suppl). 3615–3615. 1 indexed citations

13.

Mellinghoff, Ingo K., Martin J. van den Bent, Jennifer Clarke, et al.. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.. Journal of Clinical Oncology. 38(15_suppl). TPS2574–TPS2574. 11 indexed citations

14.

Alfaro-Munoz, Kristin, John Frederick De Groot, Emily Yu, et al.. (2019). Building a data foundation: How MD Anderson and Palantir are partnering to accelerate research and improve patient care.. Journal of Clinical Oncology. 37(15_suppl). e18077–e18077. 3 indexed citations

15.

Touat, Mehdi, Adrian M. Dubuc, David M. Meredith, et al.. (2018). ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. Journal of Clinical Oncology. 36(15_suppl). 2003–2003.

16.

Alexander, Brian M., Lorenzo Trippa, Sarah Gaffey, et al.. (2017). Individualized screening trial of innovative glioblastoma therapy (INSIGhT).. Journal of Clinical Oncology. 35(15_suppl). TPS2079–TPS2079. 11 indexed citations

17.

Reardon, David A., John Frederick De Groot, Howard Colman, et al.. (2016). Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).. Journal of Clinical Oncology. 34(15_suppl). 2010–2010. 31 indexed citations

18.

Prados, Michael, John G. Kuhn, Howard Colman, et al.. (2016). Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium.. Journal of Clinical Oncology. 34(15_suppl). 2031–2031. 2 indexed citations

19.

Butowski, Nicholas, Howard Colman, John Frederick De Groot, et al.. (2014). A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.. Journal of Clinical Oncology. 32(15_suppl). 2023–2023. 15 indexed citations

20.

Wen, Patrick Y., W.K. Alfred Yung, Ingo K. Mellinghoff, et al.. (2014). Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.. Journal of Clinical Oncology. 32(15_suppl). 2019–2019. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact